Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Here are the HIV treatment news stories with the most views this year.
In an ongoing trial of people on failing antiretroviral regimens, the injectable PRO 140 reduced viral load considerably.
One injection of the cloned antibody significantly reduced participants’ viral load in a recent advanced trial.
Now that he’s on PRO-140, an experimental weekly injection, Sheen “is feeling fantastic.”
The actor is part of an FDA study on the weekly injectable PRO 140.
CytoDyn’s monoclonal antibody PRO 140 injected once a week suppressed HIV in some people living with the virus for well over a year.
New questions about Charlie Sheen’s infamous visits to The Dr. Oz show.
A weekly injection of an HIV antibody boasted a 98 percent success rate among participants in a small trial.
PRO 140 was able to suppress HIV for more than two weeks after a single injection
A single IV dose of the HIV entry inhibitor PRO 140 reduced virus by nearly 100-fold for up to 10 days in a small phase IIa study
Experts think we’re about to enter a dry spell in terms of new HIV treatments, with no truly novel compounds available for treatment...
Delegates attending conference got a first look at data from a clinical trial testing injections of PRO 140, an experimental entry inhibitor
Positive early results from a Phase II clinical trial of intravenous (IV) PRO 140, an experimental HIV entry inhibitor.
Researchers once again reported promising results from an early study of PRO 140, an experimental HIV entry inhibitor.
Researchers have reported encouraging results from an early study of PRO 140, an experimental HIV entry inhibitor.
Progenics Pharmaceuticals has announced encouraging results from an early study of PRO 140, its experimental HIV entry inhibitor.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.